SDS. Durrant

S. Durrant

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


S. Durrant has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • J Morton

    Department of Haematology, Royal Brisbane Hospital, Brisbane, Australia

    2 shared publications
  • E. A. Gillett

    Bone Marrow Transplant Unit and 3Haematology Unit, Royal Brisbane Hospital, 2Haematology/Oncology Unit, Royal Children’s Hospital and 4Queensland Health Pathology Service, Brisbane, Queensland, Australia

    1 shared publication
  • G A Kennedy

    Department of Haematology, Royal Brisbane Hospital, Brisbane, Australia

    1 shared publication
  • J Bligh

    Department of Pathology, Royal Brisbane Hospital, Herston, Australia

    1 shared publication
  • J Butler

    Department of Haematology, Royal Brisbane Hospital, Brisbane, Australia

    1 shared publication
  • J. Morton

    Bone Marrow Transplant Unit and 3Haematology Unit, Royal Brisbane Hospital, 2Haematology/Oncology Unit, Royal Children’s Hospital and 4Queensland Health Pathology Service, Brisbane, Queensland, Australia

    1 shared publication

Latest Publications

  • Single institution outcomes of treatment of severe aplastic anaemia

    by P. Mollee, N. Woodward, S. Durrant, L. Lockwood, E. A. Gillett, J. Morton, J. Rowell

    Background: In severe aplastic anaemia, the treatment of choice for young patients with a human leucocyte antigen‐matched sibling is now established as allogeneic bone marrow transplantation (BMT). In older patients and in those without a matched sibling donor, immunosuppressive therapy is the usual first option. ‘Alternative’ marrow donors are emerging as an option for those without a matched sibling donor. Aims: To review 10 years of local experience in treating severe aplastic anaemia with BMT and immunosuppressive therapy with emphasis on long‐term outcomes. Methods: A retrospective analysis was performed of all patients with severe aplastic anaemia presenting to the Royal Brisbane and Royal Children’s Hos‐ pitals between 1989 and 1999. Data were abstracted regarding patient demographics, pretreatment characteristics and outcome measures, including response rates, overall survival and long‐term complications. Results: Twenty‐seven consecutive patients were identified, 12 treated with immunosuppression alone and 15 with BMT. In these two groups, transfusion independence was attained in 25% and 100%, respectively, with overall survival being 36% and 100%, respectively. Those treated with immunosuppression were significantly older (median 41.5 versus 22 years, P = 0.008). Long‐term survivors of either treatment had extremely low morbidity. Three patients carried pregnancies to term post‐transplant. Three patients received alternative donor BMT with correspondingly excellent survival. Conclusions: Patients treated with allogeneic BMT for severe aplastic anaemia enjoyed extremely good long‐term survival and minimal morbidity. Patients treated with immunosuppressive therapy had a poorer outcome reflecting their older age and different usage of therapies over the past decade. Optimal treatment strategies for severe aplastic anaemia remain to be determined. (Intern Med J 2001; 31: 337–342)


    • 1 August 1995
      • Vol. 16  (2) , 317-9

    Oncocytic metaplasia of bile duct epithelium in hepatic GVHD.

    by J Bligh, J Morton, S Durrant, N Walker

    A 15-year-old female underwent matched unrelated BMT for chemotherapy resistant ALL. She died 3 months later from septicaemia complicating grade IV GVHD. Light and electron microscopic examination of the post-mortem liver confirmed GVHD and showed oncocytic metaplasia of interlobular bile duct epithelium. We report that oncocytic metaplasia of bile duct epithelium is part of the pathological spectrum of hepatic GVHD.